|Ms. Linda F. Powers J.D.||Chairperson, CEO, Pres, Acting CFO & Chief Accounting Officer||602k||N/A||1956|
|Dr. Alton L. Boynton||Founder, Chief Scientific Officer, Sec. & Director||345k||N/A||1945|
|Dr. Marnix L. Bosch M.B.A., Ph.D., MBA||Chief Technical Officer||397k||N/A||1959|
|Ms. Jean M. Davis||Chief Information Officer||258.78k||N/A||1972|
|Mr. Leslie J. Goldman||Sr. VP & Gen. Counsel||442k||N/A||1945|
|Mr. David Innes||VP of Investor Relations||N/A||N/A||N/A|
|Mr. Pankaj R. Shah C.A., CPA||Financial Controller||N/A||N/A||N/A|
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L that is in Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.
Northwest Biotherapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.